References
- Walker PS, Hamilton JR. Identification of antibodies to red blood cell antigens. In: Fung MK, Grossman T, Hillyer CD, Westhoff CM, eds. Technical manual. 18th ed. Bethesda, MD: American Association of Blood Banks, 2014:391–424.
- Downs KA, Shulman IA. Pretransfusion testing. In: Fung MK, Grossman T, Hillyer CD, Westhoff CM, eds. Technical manual. 18th ed. Bethesda, MD: American Association of Blood Banks, 2014:367–87.
- Mazzei GA, Popovsky MA, Kopko PM. Noninfectious complications of transfusion. In: Fung MK, Grossman T, Hillyer CD, Westhoff CM, eds. Technical manual. 18th ed. Bethesda, MD: American Association of Blood Banks, 2014:665–92.
- Schonewille H, Van de Watering LMG, Brand A. Additional red blood cell alloantibodies after transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? Transfusion 2006;46:630–5.
- Wilkinson K, Harris S, Gaur P, et al. Molecular blood typing augments serologic testing and allows for enhanced matching of red blood cell for transfusion in patients with sickle cell disease. Transfusion 2012;52:381–8.
- Klapper E, Zhang Y, Figuerora P, et al. Toward extended phenotype matching: a new operational paradigm for the transfusion service. Transfusion 2010;50:536–46.
- Denomme GA. Prospects for the provision of genotyped blood for transfusion. Br J Hematol 2013;163:3–9.
- Reid ME, Lomas-Francis C, Olsson ML. The blood group antigen factsbook. 3rd ed. New York, NY: Academic Press, 2012.
- Bakanay SM, Ozturk A, Ileri T, et al. Blood group genotyping in multi-transfused patients. Transfus Apher Sci 2013;48: 257–61.
- Chou ST, Westhoff CM. The role of molecular immuno-hematology in sickle cell disease. Transfus Apher Sci 2011; 44:73–9.
- Pinto PC, Braga JA, Santos AM. Risk factors for alloimmunization in patients with sickle cell anemia. Rev Assoc Med Bras 2011;57:654–9.
- Fluit CR, Kunst VA, Schonk AM. Incidence of red cell antibodies after multiple blood transfusion. Transfusion 1990;30:532–5.
- Kacker S, Ness PM, Savage WJ, et al. Cost-effectiveness of prospective red blood antigen matching to prevent alloimmunization among sickle cell patients. Transfusion 2014;54:86–97.
- U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2013. North Rockville, MD: U.S. Food and Drug Administration. Available from: http://www.fda.gov/ BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/ TransfusionDonationFatalities/ucm391574.htm#A. Accessed April 2015.
- Vichinsky EP. The prevention and management of alloimmunization in sickle cell disease: the benefit of extended phenotype matching of red blood cells. Immunohematology 2012;28):20–3.
- Hendrickson JE, Tormey CA, Shaz BH. Red blood cell alloimmunization mitigation strategies. Transfus Med Rev 2014;28:137–44.
- Chou ST, Jackson T, Vege S. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority groups. Blood 2013;122:1062–71.
- Westhoff CM. Rh complexities: serology and DNA genotyping. Transfusion 2007;47(Suppl 1):17S–22S.
- Osby M, Shulman IA. Phenotype matching of donor red blood cell units for nonalloimmunized sickle cell disease patients. Arch Pathol Lab Med 2005;129:190–3.
- Reid ME. Overview of molecular methods in immuno-hematology. Transfusion 2007;47(Suppl 1):10S–16S.
- Reid ME. Transfusion in the age of molecular diagnostics. Hematology Am Soc Hematol Educ Program 2009:171–7.
- Moulds MM. Future of molecular testing for red blood cell antigens. Clin Lab Med 2010;30:419–29.
- Hillyer CD, Shaz BH, Winkler AM, et al. Integrating molecular technologies for red blood cell typing and compatibility testing into blood centers and transfusion services. Transfus Med Rev 2008;22:117–32.
- Elkins MB, Davenport RD, O’Malley BA, et al. Molecular pathology in transfusion medicine. Clin Lab Med 2013;33: 805–16.